Hologic, Inc. ("Hologic" or "the
Company") HOLX, a leading developer, manufacturer and supplier of
premium diagnostics products, medical imaging systems and surgical products
dedicated to serving the healthcare needs of women, today announced
organizational changes to its Diagnostics segment.
Based upon the successful progress achieved in the ongoing integration of
Gen-Probe Incorporated ("Gen-Probe"), which is proceeding ahead of schedule,
and the solid foundation of the Diagnostics segment, Hologic has accelerated
the timing of several planned organizational changes. In conjunction with the
Company's accelerated execution, Carl Hull will be retiring from his role as
Senior Vice President and General Manager of Diagnostics. Mr. Hull, who served
as Chairman, President and Chief Executive Officer of Gen-Probe until that
company was acquired by Hologic in August 2012, will continue with the Company
as a consultant up to mid-August 2013.
"We are confident that now is the right time to transition our team and we are
grateful for the deep bench of talent within the Hologic and legacy Gen-Probe
organizations who are well positioned to successfully assume greater levels of
responsibility as we continue to grow," said Rob Cascella, President and Chief
Executive Officer of Hologic. "Carl has been instrumental in the ongoing and
successful integration of Gen-Probe into Hologic that has supported our rapid
progress. We have benefitted from his experience, deep knowledge of the
industry and valuable relationships and we thank Carl for his leadership and
commitment. We look forward to his continued contributions throughout 2013,
including his support in facilitating a seamless leadership transition."
"We have a well-defined strategic path forward to grow the diagnostics
businesses globally, drive innovation and expand our technology offerings,"
said Mr. Hull. "I look forward to working with Rob and the rest of the team to
ensure that we capture the benefits of the Gen-Probe transaction for all of
our stakeholders. We are very excited about our future and are confident that
today, Hologic is well positioned to build upon its leadership role in
diagnostics as it continues to meet the expanding needs of its customers."
As part of the organizational changes, Rohan Hastie, formerly a vice president
and general manager within the Women's Health group of the Company's
Diagnostics segment, has been appointed Senior Vice President and Group
General Manager - Diagnostics, which now includes overseeing the segment's
Women's Health and Virology businesses, as well as the U.S. Diagnostics sales
team. In addition, Eric Tardif, Senior Vice President of Commercial Operations
- Diagnostics, will assume the role of Senior Vice President of Corporate
Strategy, partnering with Mr. Cascella and the business leaders to further
shape Hologic's long-range goals.
On Track to Achieve Over $40 Million in First-Year Cost Synergies:
Hologic has made significant progress in integrating Gen-Probe into its
existing Diagnostics segment. The Company remains on track to realize over $40
million in cost synergies by the end of the first year following the
acquisition and an additional $35 million in cost synergies by the end of the
third year. In addition, Hologic is continuing to drive revenue synergies by
utilizing its global sales and marketing presence to capitalize on
cross-selling opportunities to leverage its expanded molecular diagnostics
product portfolio.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: NewsManagement
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in